Strongest safety performance in five years drives 15 flow records and solid financial resultsProgress in commercial discussions strengthens line ...
(PRESS RELEASE) BASEL, 13-Feb-2026 — / EuropaWire / — Novartis has announced final Phase III results from the ALIGN study evaluating Vanrafia (atrasentan) in adults with IgA nephropathy (IgAN), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results